Roche announced results from two clinical trials for astegolimab in COPD patients. The Phase IIb ALIENTO trial showed a 15.4% reduction in exacerbation rate at 52 weeks. However, the Phase III ARNASA trial did not meet its primary endpoint, with a 14.5% reduction that was not statistically significant. Secondary endpoints were consistent, and overall exacerbations were lower than expected. Astegolimab’s safety profile was in line with previous data, with no new safety concerns. Visit rttnews.com for more health news.

Read more at Nasdaq: Roche Announces Mixed Results For Astegolimab In COPD Trials